Interphex

Pfizer has launched its combined contract manufacturing organization, Pfizer CentreOne (Booth 1235), a multi-specialty CMO focusing on API synthesis and sterile injectables fill-finish. The new brand unites Pfizer CentreSource, a global specialty API provider, and Hospira One 2 One, a sterile-injectables CMO. Pfizer acquired Hospira back in September 2015.
           
“As a combined organization, we’ve brought together the best of our manufacturing capabilities to provide a wider array of services and technologies to our biopharmaceutical partners,” said Peter Stevenson, vice president and general manager of Pfizer CentreOne. “Although Pfizer CentreOne is a new name, we’ve been providing contract manufacturing services for more than 40 years and are committed to further growing our business.” 
           
Pfizer has committed to reserve capacity for Pfizer CentreOne partner drugs across its dedicated facilities. Pfizer CentreOne’s core offerings include two primary areas of expertise: API and drug product, with a specific focus on small-molecule steroid and hormone intermediates and APIs, custom small-molecule API synthesis, and sterile injectables fill-finish.
           
Pfizer CentreOne is a CMO within Pfizer and will have its own dedicated team that reports through Pfizer’s commercial organization.